BioSign receives 510(k) approval from the US Food and Drug Administration (FDA). BioSign is approved to be marketed as an accessory to a patient monitor or clinical information system for use with non pediatric patients - see press release
BioSleep technology for insomnia evaluation is
presented at the British Sleep Society
Annual Meeting in Cambridge September
14-16th 2003. Contact
us for a copy of the slides.
Oxford
BioSignals gains FDA
clearance to market BioSomnia. Developed
from leading edge neural network technology, BioSomnia
is the first single EEG channel sleep system to
provide objective information on the quantity and
quality of sleep.
Oxford BioSignals launched BioSleep
Version 2.0B on 1st March 2001
Clinical trials of BioSleep in a home
monitoring environment were started in January
2001
BioSleep was presented at the Second Symposium
on Automatic Sleep Analysis at Geneva on
21st to 23rd November 2000. For copies of the slides
contact enquiries@oxford-biosignals.com.
EPO,
the electronic public offering company featured
the launch of Oxford BioSignals on their
web site.
Oxford BioSignals is working with Stowood
Scientific Instruments, a UK company, to
integrate BioSleep with their sleep monitoring
product, Visi2. BioSleep will be available as
an option on Visi2 soon.
Oxford
BioSignals was formed in May 2000, to exploit
the technology originally developed by Professor
Lionel Tarassenko of the University of Oxford.
The company offers solutions aimed at improving
patient care by providing clinicians with new
comprehensive decision support tools.
Oxford BioSignals, University of Oxford and Rolls-Royce celebrate business value from award winning Engine Health Monitoring technology read more
EPO,
the electronic public offering company featured
the launch of Oxford BioSignals on their
web site. 
Oxford
BioSignals was formed in May 2000, to exploit
the technology originally developed by Professor
Lionel Tarassenko of the University of Oxford.
The company offers solutions aimed at improving
patient care by providing clinicians with new
comprehensive decision support tools.
